Fasiglifam (TAK‐875) has dual potentiating mechanisms via Gαq‐GPR40/FFAR1 signaling branches on glucose‐dependent insulin secretion

Fasiglifam (TAK‐875) is a free fatty acid receptor 1 (FFAR1)/G‐protein–coupled receptor 40 (GPR40) agonist that improves glycemic control in type 2 diabetes with minimum risk of hypoglycemia. Fasiglifam potentiates glucose‐stimulated insulin secretion (GSIS) from pancreatic β‐cells glucose dependent...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakuma, Kensuke, Yabuki, Chiori, Maruyama, Minoru, Abiru, Akiko, Komatsu, Hidetoshi, Negoro, Nobuyuki, Tsujihata, Yoshiyuki, Takeuchi, Koji, Habata, Yugo, Mori, Masaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876146/
https://www.ncbi.nlm.nih.gov/pubmed/27433346
http://dx.doi.org/10.1002/prp2.237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876146/
https://www.ncbi.nlm.nih.gov/pubmed/27433346
http://dx.doi.org/10.1002/prp2.237

Ejemplares similares